Cerulean Scientific


Medical device company developing implantable and indwelling devices designed to resist clogging, obstruction, and biofouling. Works with academic partners, publishes in peer-reviewed journals, and is pursuing regulatory clearance and commercialization of neurosurgical and vascular access devices using an omniphobic surface engineering approach.

Industries

N/A

Nr. of Employees

small (1-50)

Cerulean Scientific

701 W Main St, Suite 410, Durham, NC 27701


Patents

Fluoropolymer based anti-thrombotic coatings

US-12233186-B2

View Details

Packaging for medical devices coated with perfluorinated liquids or dispersions thereof

US-11998369-B2

View Details

Products

Ventricular catheters and external ventricular drains

Implantable neurosurgical drainage devices engineered with anti-fouling surface treatments to reduce occlusion and cellular attachment.

Hemodialysis catheters and vascular grafts

Vascular access devices treated with anti-biofouling surface engineering to improve patency and reduce fibrin sheath formation in preclinical testing.


Services

Partnership-based research and development to translate surface engineering concepts into implantable devices through joint studies and preclinical testing.

Administration and execution of externally funded research programs supporting device development and regulatory advancement.

Expertise Areas

  • Anti-biofouling surface engineering
  • Implantable catheter and graft design
  • Preclinical in vivo device testing
  • Translational research and academic partnerships
  • Show More (3)

Key Technologies

  • Omniphobic surface coatings
  • Biofouling-resistant surface engineering
  • Implantable catheter and graft design
  • Preclinical animal models
  • Show More (1)

News & Updates

Announcement of a $5.386M Congressionally Directed Medical Research Programs (CDMRP) grant to fund studies advancing anti-fouling neurosurgical devices toward 510(k) clearance.

Journal article reporting increased survival time, improved clinical outcome scores, and reduced cell attachment on anti-fouling ventricular catheters compared with standard controls.

Company references to publications in journals including Nature Biotechnology and Scientific Reports illustrating foundational and supporting research.

Recipient of a Congressionally Directed Medical Research Programs award of $5,386,587 to support development of anti-fouling neurosurgical devices.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.